by Comite Web | Oct 22, 2025 | Sin categorizar
On October 5–7, 2025, the annual United European Gastroenterology (UEG) Week in Berlin hosted the inaugural Digestive Disease Mechanisms (DDM) Summit, organized by Francisco X. Real, Mathias Heikenwälder, and Maria Sibilia. The DDM Summit marked the first basic research–focused program within UEG Week, which has traditionally been recognized for its clinical orientation. This new initiative aims to bridge the gap between clinicians and scientists, fostering translational collaboration across the fields of gastroenterology, hepatology, and pancreatic research.
The ALIPANC consortium was represented in Berlin by Francisco X. Real, Núria Malats, Chengsi Wu, and Mikhail Chesnokov. Chengsi Wu delivered an oral presentation on how gut microbiome dynamics shape pancreatic health in the context of Nr5a2 gene haploinsufficiency, presenting new evidence that microbiome-targeted strategies could offer preventive opportunities for pancreatic disease. Mikhail Chesnokov presented a poster revealing a novel role of the transcription factor NR5A2 in the regulation of intestinal epithelial cell fate and colon homeostasis. In recognition of their contributions, both researchers received travel grants to attend the summit, and Chengsi Wu was appointed as chair of the “Immune Mechanisms in Gastrointestinal Diseases” session.
The DDM Summit brought together leading experts in pancreatic disease research, including Grainne O’Kane, Dieter Saur, Laura Machesky, Andreas Trumpp, and Tuomas Tammela. Other Spanish scientists, including Eduard Batlle (IRB Barcelona), Nabil Djouder (CNIO), and Guadalupe Sabio (CNIO) delivered invited talks on colorectal and liver cancer.
The event fostered a productive exchange between clinicians and basic researchers, highlighting the growing integration of scientific discovery and medical practice within the UEG community.
Through its active participation, ALIPANC reaffirmed its commitment to supporting early-career scientists and promoting excellence in basic and translational research on the mechanisms underlying pancreatic disease. Following its successful debut, the DDM Summit is expected to become a regular feature of future UEG Week meetings.
by Comite Web | Oct 12, 2025 | Sin categorizar
The application period for the ALIPANC 2025 Elections is now open, on the occasion of the renewal of the ALIPANC Directive Board.
Below, we attach the related documentation:
📑 Application_form_ALIPANC2025
📓 Election_rules_ALIPANC2025
by Comite Web | Oct 9, 2025 | Sin categorizar
We share the schedule of upcoming sessions included in our monthly meetings, as well as the scientific activities planned for the coming months:
🔹 2025
🗓️ November 4, 2025
Title: Targeting the KRAS signaling network in pancreatic cancer
Speaker: Vicky Liaki (Barbacid Lab, CNIO, Madrid)
🗓️ December 2, 2025
Title: Development of Neoantigen-based Vaccines in Pancreatic Cancer
Speaker: Núria de la Iglesia (Irsicaixa, Badalona)
🔹 2026
🗓️ January 13, 2026
Title: PREVENPANC. Spanish Multicenter Study for the Prevention of Pancreatic Cancer.
Speaker: Leticia Moreira (Hospital Clínic, Barcelona)
🗓️ February 3, 2026
Title: Variation in CFTR expression can contribute to pancreatic cancer aggressiveness
Speaker: Raquel Ibáñez (VHIR – Xavier Molero Group)
🗓️ March 13, 2026
Event: Third ALIPANC Scientific Meeting. Face-to-face meeting in Madrid, which will give us the opportunity to share experiences, interact and foster new collaborations.
We will provide more details as the schedule is finalized, but we invite you to reserve this date in your calendars.
We encourage all members of the alliance to present their research at upcoming scientific meetings.
Your participation is key to strengthening the collaboration and further advancing our understanding of pancreatic cancer.
by Comite Web | Sep 19, 2025 | Sin categorizar
The second edition of the Botton-Champalimaud International Pancreatic Cancer Conference (BCIPCC) will take place from October 29th to November 1st, 2025, at the Botton-Champalimaud Pancreatic Cancer Centre in Lisbon.
Following the success of the inaugural 2024 conference, the event will again bring together global experts and healthcare professionals to discuss the latest advancements in pancreatic cancer diagnosis, treatment, and care. Topics will include innovative diagnostic techniques, emerging therapies, and cutting-edge research.
Have a look at the program!
More information and registration: https://www.bcipcc.org
by Comite Web | Sep 11, 2025 | Sin categorizar
On September 17th, the conference “Pancreatic Cancer: challenges and future perspectives” will take place at the Ramón Areces Foundation. Leading international experts, including members of ALIPANC, will present advances in basic, translational and clinical research.
Four sessions will address the most recent advances on the origin and molecular evolution of the tumor, mechanisms of resistance and new therapeutic strategies and clinical research.
Attendance is free with prior online registration – Don’t miss it!
More information: Fundación Ramón Areces.
by Comite Web | Jul 29, 2025 | Sin categorizar
At the 2025 ASCO congress it was presented the positive results of the PANOVA-3 trial. This is the first and the only positive trial in locally advanced pancreatic cancer (LA-PDAC)
Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation.
571 newly diagnosed LA-PDAC were randomly assigned to received gemcitabine and nab-paclitaxel with or without TTFields.
Overall survival was significantly prolonged using TTFields with chemotherapy versus chemotherapy alone (median 16.2months, vs 14.2 months, HR 0.82, p 0.039).
Progression free survival, local progression free survival, and overall response rate were not improved.
Importantly pain free survival was significantly prolonged with TTFields plus chemotherapy (median 15.2 months vs 9.1 months, HR0.74, p 0.027).
Distant progression free survival was longer in patients treated with TTFields plus chemotherapy (13.9 months vs 11.5 months, HR 0.74, p 0.022).
Device-related skin adverse events were experienced by 76.3% of patients, but only 7.7% of patients presented grade 3 adverse events.
This trial was published in J Clin Oncol on May 31, 2025, and the lead author of the study is Dr. Teresa Macarulla, a distinguished member of ALIPANC.
The full study can be accessed at the following link: https://pubmed.ncbi.nlm.nih.gov/40448572/
